Heart stem cell trial pulled before it even started
NCT ID NCT03902067
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial aimed to test whether umbilical cord stem cells, delivered through a catheter into heart arteries, could safely improve heart function in people with severe heart damage after a major heart attack. It was designed for patients with very weak hearts (ejection fraction below 35%) and large scars. However, the study was withdrawn before enrolling any participants, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- umbilical cord mesenchymal stem cells (UC-MSC)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYOCARDIAL INFARCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Shanghai, Shanghai Municipality, 200233, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which strategy wins for heart attack patients with multiple blocked arteries?
- Can a Plant-Based diet calm the immune system after a heart attack?
- Can a quick shot stop a heart attack in its tracks?
- A sharper eye on the heart: new blood test aims to spot heart attacks faster
- Can a Stick-On AI patch replace wires for heart monitoring after surgery?
- A digital coach for the heart: app aims to keep risk factors in check after a heart attack